AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 242 min read$UTHR

ROTHBLATT MARTINE A sold $5.1M of UTHR

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $537.74 ($534.09–$539.90, $5.11M total) across 7 trades on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Jun 24, 2026, 12:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with upcoming company catalysts, but the pre-arranged nature of the plan limits inference about near-term fundamentals.

02

Market read

A $5.11M CEO/Chair open-market sale under 10b5-1 is a modest sentiment datapoint rather than a fundamental catalyst.

03

What to watch

The article provides only the sale details; it does not include any concurrent insider buys, changes in guidance, or operational/regulatory developments that would connect the sale to fundamentals.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-06-24) discloses the 2026-06-22 sales

Background

The article is an SEC Form 4 insider transaction: ROTHBLATT MARTINE A (United Therapeutics CEO/Chair) sold shares on 2026-06-22 under a Rule 10b5-1 plan; the filing was made 2026-06-24.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

United Therapeutics CEO/Chair sold 9,500 shares in open-market transactions under a 10b5-1 plan, totaling about $5.11M.

Expected impact

Likely limited immediate price impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The filing is a primary Form 4 disclosure with a sizable dollar amount, but it explicitly states the trades were pre-arranged under a Rule 10b5-1 plan, reducing interpretability as a new negative view.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

Regional

None indicated; US-listed issuer filing only.

Global

None indicated; no international transaction or regulatory action mentioned.

Counterpoint

What could challenge this read

Because the sales were executed under a pre-arranged 10b5-1 plan, the disclosure may reflect routine liquidity/compensation rather than a change in outlook.

Key entities

  • issuer
    United Therapeutics Corp

    Subject of the Form 4 insider sale disclosure (UTHR).

  • insider
    ROTHBLATT MARTINE A

    CEO & Chairperson who sold 9,500 shares across seven trades under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

SEP 10
$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min
SEP 9
$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min
SEP 9
$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min